新型冠状病毒肺炎治疗新策略：间充质干细胞疗法

当前新型冠状病毒肺炎（corona virus disease 2019, COVID-19）全球蔓延，全球累计确诊超过16 750万例。新型冠状病毒传播具有高传染性，人体感染后具有呼吸道症状、发热、严重呼吸综合征、器官衰竭，甚至死亡。对于COVID-19目前没有特异性治疗方法，大部分治疗方案采用的是对症支持治疗，但是预后差。间充质干细胞（mesenchymal stem cells, MSCs）不仅能够修复损伤的肺组织，还具有调控免疫、抗炎等作用，具有良好的临床应用前景。本文将对MSCs应用于新冠病毒肺炎治疗做一综述，以供同行参考。

Mesenchymal Stem Cells: a new discovery in the treatment of novel coronavirus pneumonia

Currently, the corona virus disease 2019 was spreading globally, and more than 167.5 million confirmed cases worldwide. The new corona virus was highly contagious. The human body would have respiratory symptoms, fever, severe respiratory syndrome, organ failure, and even death after being infected with the virus. At present, there was no specific treatment for COVID-19. Most of the treatments were symptomatic and supportive treatment, and the prognosis was poor. Mesenchymal stem cells could not only repair damaged lung tissue, but also regulate immunity and anti-inflammatory effects, and had good clinical application prospects. We will review the application of MSCs in the treatment of COVID-19 for the reference of colleagues.